Medpace Holdings Inc vs Rivian Automotive, Inc. — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Rivian Automotive, Inc. trades at $13.96 (market cap $20.75B). The key difference: Rivian Automotive, Inc. is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Rivian Automotive, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Rivian Automotive, Inc. for 61 Days on average.
| MEDP | RIVN | |
|---|---|---|
Market Cap | $16.82B | $20.75B |
Volume | 223,093 | 26,144,654 |
Sector | Health | Consumer Cyclical |
52-Week High | $630.19 | $22.45 |
52-Week Low | $393.42 | $12.50 |
Typical Hold Time | 14 Days | 61 Days |
Enterprise Value | $16.44B | $20.79B |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
Rivian Automotive (RIVN) trades at $13.96, down 2.65% amid bearish technical signals despite strong Q3 2026 delivery results. The company reported record production of 19,751 vehicles and deliveries of 19,248, beating estimates but maintaining unchanged guidance. Fundamentally, RIVN shows improving revenue growth ($5.39B in 2025) but continues significant losses (-$3.65B net income) with negative margins. Analyst consensus remains cautiously optimistic with a $16.89 price target, though technical indicators show 18 sell signals versus 2 buy signals.
Rivian's investment case balances strong delivery growth and R2 SUV ramp-up against persistent cash burn and competitive EV market pressures. The stock offers upside to analyst targets but faces execution risks in achieving profitability. Key catalysts include R2 production scaling and autonomy technology rollout, while main risks involve cash flow sustainability and intense industry competition.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →